News for IMPL Stock

Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale Impel Pharmaceuticals Announces Exploration of Strategic Alternatives Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023 Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine Medications Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors Cellarity Strengthens Executive Leadership Team Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual Meeting Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023 Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in September Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD) Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022 Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25 Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022 Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021 Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray for the Acute Treatment of Migraine Carepoint Pharmacy Selected by Impel NeuroPharma as a Digital Pharmacy Partner for the Launch of Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering Impel NeuroPharma Announces Launch of Proposed Public Offering Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine Impel NeuroPharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update Impel NeuroPharma to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021 Impel NeuroPharma Announces Publication of Pivotal Phase 3, Open-Label Stop 301 Study of INP104 (TRUDHESA™) for Treatment of Acute Migraine in the Journal Headache Impel NeuroPharma to Present at the 2021 Wedbush Pacgrow Virtual Healthcare Conference Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference Impel NeuroPharma Announces First Quarter 2021 Financial Results and Provides Business Update Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP-301 Study at The 63rd Annual Meeting of the American Headache Society Impel NeuroPharma Launches Reroute Migraine Relief, Educational Initiative That Brings to Life the Underrecognized Connection Between Migraine, the Brain and Gut Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering